ArriVent reports Q3 2024 cash of $282.9M, net loss $59.9M; firmonertinib clinical progress highlighted

ArriVent BioPharma, Inc.

2024-Q3 EPS reported -$1.95

Cash and cash equivalents $282.9M as of Sept 30, 2024; expected to fund operations into 2026.
Net loss $59.9M for nine months ended Sept 30, 2024; R&D expenses $58.9M, G&A $11.8M.
Positive interim firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC 2024 with CNS activity.
Phase 3 FURVENT trial top-line data for firmonertinib in EGFR exon 20 NSCLC expected in 2025.
Dose expansion for firmonertinib plus SHP2 inhibitor expected in Q4 2024; ADC candidate selection by early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.